Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Therapy-related myelodysplastic syndromes-specific risk stratification: Are we putting the cart before the horse?
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Rethinking clinical trial endpoints in myelodysplastic syndromes.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Whole exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
|
Dec 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA As compared with BM
|
Aug 2017
|
Leukemia
|
aplastic anemia
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
|
Jun 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
|
Sep 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|